FDA-approved
Digestive & weight
Octreotide
Evidence
FDA approved
Class
Somatostatin analog
KEY TAKEAWAY
Octreotide is an eight-amino-acid synthetic version of somatostatin that lasts much longer than the natural hormone. It is sold as Sandostatin and Mycapssa. The FDA approved octreotide (Sandostatin) in 1988. It is approved for acromegaly and for symptoms of certain neuroendocrine tumors, and an oral form (Mycapssa) is approved for acromegaly.
Written by the Veylo editorial team · Updated
November 2026
What it is
Somatostatin analog
Approved for
Acromegaly and symptoms of certain neuroendocrine tumors
Key fact
The FDA approved octreotide (Sandostatin) in 1988. It is approved for acromegaly and for symptoms of certain neuroendocrine tumors, and an oral form (Mycapssa) is approved for acromegaly.
Route
Injection under the skin or into muscle; an oral capsule is also approved
Evidence strength
FDA approved
Octreotide is an eight-amino-acid synthetic version of somatostatin that lasts much longer than the natural hormone. It is sold as Sandostatin and Mycapssa.
It binds somatostatin receptors and slows the release of growth hormone, insulin, glucagon and several gut hormones.
The FDA approved octreotide (Sandostatin) in 1988. It is approved for acromegaly and for symptoms of certain neuroendocrine tumors, and an oral form (Mycapssa) is approved for acromegaly.
Acromegaly and symptoms of certain neuroendocrine tumors.
Gallstones, nausea, diarrhea and changes in blood sugar are the most common effects.
U.S. FDA prescribing information for Octreotide. DailyMed, National Library of Medicine.
Veylo content is educational and not medical advice. Peptides that are not FDA-approved are not approved for the uses described.